Warning Letters: DanChem Technologies and Medsep - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Warning Letters: DanChem Technologies and Medsep

Pharmaceutical Technology

Warning Letters: DanChem Technologies and Medsep

The US Food and Drug Administration this week released drug-product warning letters sent to DanChem Technologies (Danville, VA, www.danchem.com) and Medsep Corp. (Covina, CA).

On March 3, FDA's Baltimore (MD) District Office sent a three-page letter to DanChem, an active-pharmaceutical-ingredient maker. The letter cited "physical filth" contamination found by a customer in several lots of calcium polycarbophil. The warning also cited "significant violations of current good manufacturing practice" found during agency inspections last fall, including:
  • blending out-of-specification calcium polycarbophil with in-spec batches to bring the combined batches within specification;
  • omitting ingredient names and weights from batch records;
  • maintaining "inaccurate" disposal records by labeling, disposing of, and recording debris-filled ontainers as "rejected API";
  • failure to review batch records that indicated that the amount of material produced exceeded the capacity of the processing equipment; and
  • failure to investigate foreign material found in manufacturing equipment.

On Feb. 15, the Los Angeles District Office (Irvine, CA) sent a letter to Medsep (a subsidiary of Pall Corp., East Hills, NY, www.pall.com), dealing mainly with procedural and record-keeping shortcomings in the manufacture of bacterial detection devices used with oxygen analyzers. The inspection did note, however, that "Anticoagulant Citrate Phospahate Double Dextrose Solution with AS-3 Nuhicel Additive System" (used in blood collection bags manufactured at the same facility) are regulated under drug CGMPs, and cited inadequacies in the batch production and control records.

–Doug McCormick

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
9%
All of the above.
45%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here